News headlines about LivaNova (NASDAQ:LIVN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. LivaNova earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.3643423139114 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
A number of brokerages recently issued reports on LIVN. Canaccord Genuity raised their target price on LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. BidaskClub lowered LivaNova from a “buy” rating to a “hold” rating in a research note on Saturday, March 10th. Needham & Company LLC restated a “buy” rating and issued a $104.00 target price (up previously from $97.00) on shares of LivaNova in a research note on Wednesday, February 28th. Zacks Investment Research lowered LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. Finally, ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. LivaNova presently has a consensus rating of “Buy” and a consensus price target of $81.43.
Shares of LIVN opened at $86.89 on Friday. The stock has a market cap of $4,162.17, a price-to-earnings ratio of 26.25, a P/E/G ratio of 2.69 and a beta of 0.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.79 and a current ratio of 2.14. LivaNova has a fifty-two week low of $49.68 and a fifty-two week high of $92.31.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.10. The company had revenue of $278.40 million for the quarter, compared to the consensus estimate of $278.48 million. LivaNova had a positive return on equity of 9.37% and a negative net margin of 2.10%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the firm earned $0.83 EPS. analysts expect that LivaNova will post 3.2 EPS for the current year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $83.32, for a total transaction of $83,320.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David S. Wise sold 1,500 shares of the firm’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $88.17, for a total value of $132,255.00. The disclosure for this sale can be found here. Insiders have sold a total of 4,500 shares of company stock worth $386,035 over the last ninety days. 0.28% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “LivaNova (LIVN) Getting Somewhat Positive Media Coverage, Report Finds” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/06/livanova-livn-getting-somewhat-positive-media-coverage-report-finds.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.